ABBV

abbv-202602040001551152false00015511522026-02-042026-02-040001551152us-gaap:CommonStockMemberexch:XNYS2026-02-042026-02-040001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec1250SeniorNotesDue2031Memberexch:XNYS2026-02-042026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2026

ABBVIE INC.

(Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.  Results of Operations and Financial Condition

On February 4, 2026, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated February 4, 2026 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:February 4, 2026By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202601070001551152false00015511522026-01-072026-01-070001551152us-gaap:CommonStockMemberexch:XNYS2026-01-072026-01-070001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2026-01-072026-01-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2026

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2025 are expected to include acquired IPR&D and milestones expense of $1.3 billion on a pre-tax basis, representing an unfavorable impact of $0.71 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on October 31, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2025 acquired IPR&D and milestones expense, is $9.90 - $9.94. AbbVie’s fourth quarter 2025 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2025 acquired IPR&D and milestones expense, is $2.61 - $2.65.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the fourth quarter of 2025.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under the Exchange Act or under the Securities Act of 1933, as a

abbv-202510310001551152false00015511522025-10-312025-10-310001551152us-gaap:CommonStockMemberexch:XNYS2025-10-312025-10-310001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-10-312025-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

On October 31, 2025, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated October 31, 2025 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:October 31, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer